VEGFA and cancer: Bevacizumab, for example, a VEGF antagonist with over 15 years of market data, has been found to decrease the growth and metastasis of several cancer types, including metastatic colorectal, metastatic breast, non-small-cell lung, renal cell carcinoma, glioblastoma, ovarian, and cervical cancers [5].